Aduro Biotech Inc.

Johns Hopkins University

Anza Therapeutics, Inc.

Dirk G Brockstedt

Thomas W Dubensky, Jr

David N Cook

Keith Sadoon Bahjat

Meredith Lai Ling Leong

John E Hearst

David Philip Cook

Peter M Lauer

William G Hanson

William S Luckett, Jr

Meredith Leong

Marcella Fasso

Thomas W Dubensky

Justin Skoble

Charles George Drake

Christopher Steven Rae

David Cook

William Stanford Luckett, Jr

Provided herein are prime-boost regimens and materials used therein. The prime-boost regimens enhance the immune response to a target antigen. The vaccines used for boost are comprised of recombinant attenuated metabolically activethat encodes an expressible antigen that is cross-reactive with the target antigen. In some examples, the immune response is a cellular immune response.

[object Object]

Provided herein are compositions and methods for eliciting an immune response in a subject. In particular, the present disclosure is directed to immunogenic fusion proteins and methods of eliciting an immune response using host cells comprising nucleic acid molecules encoding said fusion proteins.

Immunogenic fusion proteins for the treatment of cancer

The present invention provides nucleic acids, expression systems, and vaccine strains which provide efficient expression and secretion of antigens of interest into the cytosol of host cells, and elicit effective CD4 and CD8 T cell responses by functionally linking Listerial or other bacterial signal peptides/secretion chaperones as N-terminal fusion partners in translational reading frame with selected recombinant encoded protein antigens. These N-terminal fusion partners are deleted (either by actual deletion, by mutation, or by a combination of these approaches) for any PEST sequences native to the sequence, and/or for certain hydrophobic residues.

Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof

Methods and compositions using listeria for enhancing immunogenicity by prime boost

Methods and compositions using listeria for adjuvant treatment of cancer

The present invention providesthat are attenuated for entry into non-phagocytic cells as well as a variety of methods of inducing immune responses involving administering compositions comprising the attenuated. Some of the attenuatedare mutantthat comprise at least one mutation in a gene encoding an invasin, such as an internalin. Some of the attenuatedare further attenuated for cell-to-cell spread. Pharmaceutical compositions and vaccines useful in the methods of the invention are further provided. Methods of making and improving vaccines are also provided.

Free-living microbes are provided in which the nucleic acid has been modified so that the microbe is attenuated for proliferation and/or which comprise genetic mutations that attenuate the ability of the microbe to repair its nucleic acid. Methods of using the modified microbes for the loading, activation, and/or maturation of antigen-presenting cells are also provided. Vaccine compositions comprising the modified microbes and/or the antigen-presenting cells and methods of using the vaccines are also provided. The microbes may be further modified to include heterologous antigens, such as tumor antigens or infectious disease antigens, for use as a vaccine against cancer or infectious diseases.

Modified free-living microbes, vaccine compositions and methods of use thereof

Growing community of inventors

Richmond, CA, United States of America

Dirk G Brockstedt